Overview

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
GSK1349572 is an integrase inhibitor that is currently being evaluated for the treatment of HIV infection. The primary objective of this study is to determine whether the addition of a proton pump inhibitor, omeprazole, to GSK1349572 impacts the blood levels of GSK1349572. It will also evaluate if a high fat meal impacts the blood levels of GSK1349572. In addition, the safety, tolerability, and pharmacokinetics of single supratherapeutic (high) dose of GSK1349572 will be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Collaborator:
Shionogi
Treatments:
Dolutegravir
Integrase Inhibitors
Omeprazole
Proton Pump Inhibitors